1. Clinical & Scientific Overview
Sitagliptin Phosphate (TIP-MED-000046, Reference Code [4.2]) is classified under
Antidiabetic Medicines, Insulins & GLP-1 Agonists (Ch 04) as a Dipeptidyl Peptidase-4 (DPP-4) Inhibitor (Gliptin); Incretin Enhancer.
Within the Indian regulatory and compendial framework, it is governed under Schedule H & Schedule G Prescription Drug ('Caution: It is dangerous to take this preparation except under medical supervision' — Drugs Rules 1945).
Amaryl (Sanofi), Glimisave (Eris), Glimestar (Mankind), Zoryl (Intas)
Oral Film-Coated Tablets: 25 mg, 50 mg, 100 mg
3. Mechanism of Action & Pharmacodynamics
Dipeptidyl Peptidase-4 (DPP-4) Inhibitor (Gliptin); Incretin Enhancer acting on target receptor/enzyme pathways in Antidiabetic Medicines, Insulins & GLP-1 Agonists (Ch 04): clinical efficacy is mediated via Dipeptidyl Peptidase-4 (DPP-4) Inhibitor (Gliptin); Incretin Enhancer for Type 2 diabetes mellitus as an adjunct to diet and exercise (monotherapy when metformin is contraindicated, or in dual/triple therapy with metformin, SGLT2i, sulfonylureas, or insulin)..
4. Therapeutic Indications & Evidence-Supported Uses
- Type 2 diabetes mellitus as an adjunct to diet and exercise (monotherapy when metformin is contraindicated, or in dual/triple therapy with metformin, SGLT2i, sulfonylureas, or insulin)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: 100 mg once daily (or 50 mg twice daily when given in FDC with metformin). Renal Dose Adjustment: Moderate CKD (eGFR 30 to <45 mL/min): 50 mg once daily. Severe CKD (eGFR <30 mL/min or ESRD/dialysis): 25 mg once daily. Follow physician prescription.
Administration & Meal Timing: With or without food (if in FDC with metformin, take WITH meals). | Once daily in the morning (or twice daily with breakfast and dinner if FDC).
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Strictly renal-function dependent (~79% excreted unchanged in urine)! Must reduce dose to 50 mg OD for eGFR 30–44 mL/min and 25 mg OD for eGFR <30 mL/min. Hepatic: No dose adjustment needed in mild-to-moderate hepatic impairment (Child-Pugh A/B).
Renal: Strictly renal-function dependent (~79% excreted unchanged in urine)! Must reduce dose to 50 mg OD for eGFR 30–44 mL/min and 25 mg OD for eGFR <30 mL/min. Hepatic: No dose adjustment needed in mild-to-moderate hepatic impairment (Child-Pugh A/B).
Renal: Strictly renal-function dependent (~79% excreted unchanged in urine)! Must reduce dose to 50 mg OD for eGFR 30–44 mL/min and 25 mg OD for eGFR <30 mL/min. Hepatic: No dose adjustment needed in mild-to-moderate hepatic impairment (Child-Pugh A/B).
7. Contraindications, Precautions & High-Risk Warnings
- Contraindicated in Type 1 diabetes, diabetic ketoacidosis, and history of gliptin-induced acute pancreatitis or serious hypersensitivity/angioedema. Never combine with a GLP-1 receptor agonist (semaglutide, liraglutide, dulaglutide—redundant mechanism).
Key Clinical Precautions: Renal: Strictly renal-function dependent (~79% excreted unchanged in urine)! Must reduce dose to 50 mg OD for eGFR 30–44 mL/min and 25 mg OD for eGFR <30 mL/min. Hepatic: No dose adjustment needed in mild-to-moderate hepatic impairment (Child-Pugh A/B).
8. Adverse Effects Profile
- Nasopharyngitis, upper respiratory tract symptoms, headache, mild GI discomfort; weight-neutral and very low intrinsic risk of hypoglycaemia unless combined with a sulfonylurea or insulin.
- Acute pancreatitis (persistent, severe mid-epigastric abdominal pain radiating to the back with vomiting), bullous pemphigoid (blistering skin lesions in elderly), severe disabling polyarthralgia (joint pain), angioedema (especially when co-administered with ACE inhibitors).
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Slightly increases plasma digoxin levels (monitor in narrow therapeutic index patients)
- When added to a sulfonylurea (glimepiride/gliclazide) or insulin, a dose reduction of the secretagogue/insulin is often needed to prevent hypoglycaemia
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Explain that sitagliptin works intelligently in a glucose-dependent manner—stimulating insulin release only when blood sugar rises after meals, so it rarely causes low blood sugar or weight gain by itself. Instruct the patient to stop the drug and seek urgent medical care if severe, persistent stomach pain radiating to the back occurs.
- Meal & Clock Timing Instruction: With or without food (if in FDC with metformin, take WITH meals). (Once daily in the morning (or twice daily with breakfast and dinner if FDC).)
- Missed Dose Protocol: Take as soon as remembered on the same day; if close to the next day's dose, skip. Never double the dose.
- Geriatric Dispensing Pearl: Excellent safety profile in elderly CGHS patients (no orthostasis, weight gain, or intrinsic hypoglycaemia). Audit the prescription carefully to ensure the patient is not taking both a generic Sitagliptin tablet from the CGHS counter and a branded Vildagliptin/Teneligliptin FDC from a private prescription.
Storage, Stability & Dispensing Safeguards: COLD CHAIN MANDATORY (2°C–8°C): Store in a pharmaceutical refrigerator between 2°C and 8°C; DO NOT FREEZE. Protect from light and heat during dispensing.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 04 [4.2] (p. 45)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [4.16] Insulin Lispro (Rapid-Acting & Biphasic Premixed 25/75 or 50/50) — Rapid-Acting Recombinant Human Insulin Analogue (B28 Lysine and B
- [4.17] Linagliptin — Dipeptidyl Peptidase-4 (DPP-4) Inhibitor — Biliary/Non-Renally Cl
- [4.18] Saxagliptin & Alogliptin — Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (Schedule H)
- [4.19] Repaglinide — Short-Acting Meglitinide Prandial Insulin Secretagogue (Schedule
